Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KRMD
stocks logo

KRMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
10.50M
+18.81%
-0.022
+125%
11.30M
+17.24%
-0.015
-25%
Estimates Revision
The market is revising Upward the revenue expectations for KORU Medical Systems, Inc. (KRMD) for FY2025, with the revenue forecasts being adjusted by 1.69% over the past three months. During the same period, the stock price has changed by 39.90%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-37.5%
In Past 3 Month
Stock Price
Go Up
up Image
+39.90%
In Past 3 Month
Wall Street analysts forecast KRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast KRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.680
sliders
Low
4.00
Averages
5.00
High
6.00
Current: 5.680
sliders
Low
4.00
Averages
5.00
High
6.00
Craig-Hallum
Buy
maintain
$6
2025-11-13
Reason
Craig-Hallum
Price Target
$6
2025-11-13
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Koru Medical to $6.25 from $6 and keeps a Buy rating on the shares following Koru's strong quarter, as international growth continues to inflect and the core U.S. SCIg business delivers above-market performance. Overall, revenue grew 27% year-over-year, surpassing expectations, and guidance was raised.
Piper Sandler
Neutral
maintain
$4
2025-08-07
Reason
Piper Sandler
Price Target
$4
2025-08-07
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Koru Medical to $4 from $3.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results that beat Street, including revenue of $10.2M/+21% year-over-year as U.S./International grew 15%/34%, respectively. Management also nudged 2025 revenue guidance higher by $1M, reiterated its gross margin percentage outlook, and pointed to positive cash generation in the second half of the year. In general, a solid quarter with upside balanced across the company's three segments, although Piper would still like to see better translation of the strong top-line growth to P&L leverage.
Piper Sandler
Jason Bednar
Neutral
downgrade
2025-05-08
Reason
Piper Sandler
Jason Bednar
Price Target
2025-05-08
downgrade
Neutral
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Koru Medical to $3.50 from $4.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q1 results that beat Street, including revenue of $9.6M/+17.5% year-over-year as U.S./International grew 16%/36%, respectively. The beat was wide enough for management to bump 2025 revenue guidance higher by $0.5M, Piper says, adding that it's encouraging to see gross margin percentage durability despite the geographic mix shift, and management also highlighted plans to submit for approval later this year for two commercialized drugs on the company's Freedom Infusion System.
Piper Sandler
Jason Bednar
Buy
to
Hold
Downgrades
$4.5
2025-02-14
Reason
Piper Sandler
Jason Bednar
Price Target
$4.5
2025-02-14
Downgrades
Buy
to
Hold
Reason
Craig-Hallum
Chase Knickerbocker
Strong Buy
Maintains
$5 → $6
2025-01-17
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$5 → $6
2025-01-17
Maintains
Strong Buy
Reason
Lake Street
Frank Takkinen
Strong Buy
Maintains
$4 → $5
2025-01-14
Reason
Lake Street
Frank Takkinen
Price Target
$4 → $5
2025-01-14
Maintains
Strong Buy
Reason
Lake Street raised the firm's price target on Koru Medical to $5 from $4 and keeps a Buy rating on the shares after the company announced preliminary Q4 revenue that beat the firm's and Street's estimates. While the preliminary release provided limited detail into what drove the beat, the firm suspects broad-based business strength given the size of the beat, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for KORU Medical Systems Inc (KRMD.O) is -454.40, compared to its 5-year average forward P/E of -32.51. For a more detailed relative valuation and DCF analysis to assess KORU Medical Systems Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-32.51
Current PE
-454.40
Overvalued PE
48.92
Undervalued PE
-113.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
169.89
Undervalued EV/EBITDA
-142.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.79
Current PS
0.00
Overvalued PS
6.53
Undervalued PS
3.06
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

KRMD News & Events

Events Timeline

(ET)
2025-11-12
16:08:14
Koru Medical increases FY25 revenue forecast to $40.5M-$41M, up from $39.5M-$40.5M
select
2025-11-12
16:07:20
Koru Medical Announces Q3 EPS of 0c, Below Consensus Estimate of 2c
select
2025-09-18 (ET)
2025-09-18
08:08:57
Koru Medical and ForCast Orthopedics Partner for Antibiotic Infusion Therapy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-18NASDAQ.COM
KORU Medical Plans to Pursue FDA Approval for FreedomEDGE Infusion System in Late 2025 to Early 2026

  • 510(k) Application Submission: KORU Medical Systems plans to submit a 510(k) application to the FDA for its FreedomEDGE Syringe Infusion System in late 2025 or early 2026, seeking clearance for use with a commercial oncology drug.

  • Infusion System Overview: The FreedomEDGE Infusion System is designed for large-volume subcutaneous drug delivery, proven with over 15 years of use, 45,000 patients, and 2 million annual infusions across more than 30 countries.

  • Multicenter Study Presentation: KORU Medical will present data from a multicenter study comparing the FreedomEDGE System to manual push techniques at the ESID/EHA/SIOPE Focused Symposium in November 2025, highlighting high satisfaction rates among nurses and patients.

  • Stock Performance: KRMD's stock has traded between $4.32 and $4.57 over the past year, closing at $4.49, reflecting a 3.94% increase in the latest trading session.

[object Object]
Preview
1.0
11-13Newsfilter
KORU Medical Systems to Attend Upcoming Investor Conferences

  • Upcoming Investor Conferences: KORU Medical Systems will participate in three investor conferences, including the Craig-Hallum Alpha Select Conference on November 18, 2025, the Canaccord Genuity MedTech Forum on November 20, 2025, and the Piper Sandler Healthcare Conference on December 2, 2025.

  • Product Overview: KORU Medical specializes in developing and commercializing patient-centric subcutaneous infusion solutions, including the Freedom Syringe Infusion System, which has been FDA cleared since 1994 and is designed for both home self-administration and use in ambulatory infusion centers.

  • Clinical Trials Support: The company also provides products for biopharmaceutical companies during clinical trials and can customize its infusion systems for various drug categories.

  • Investor Relations Contact: For more information, interested parties can visit KORU Medical's website or contact investor relations via email.

[object Object]
Preview
9.5
11-13NASDAQ.COM
KRMD Stock Increases Following Impressive Q3 Revenue Surge and Upgraded 2025 Forecast

  • Strong Q3 Performance: KORU Medical Systems reported a 27% increase in total revenue for Q3 2025, reaching $10.4 million, driven by robust international demand for its Freedom Syringe Infusion System.

  • Improved Financial Metrics: The company narrowed its net loss to $0.8 million and achieved a positive adjusted EBITDA of $0.09 million, reflecting significant operational improvements compared to the previous year.

  • Raised Revenue Guidance: KORU increased its full-year 2025 revenue outlook to between $40.5 million and $41.0 million, indicating a year-over-year growth of 20%-22%, while reaffirming its gross margin guidance.

  • Stock Performance: Following the positive earnings report, KORU's stock saw an increase of over 8% in premarket trading, reflecting investor confidence in the company's growth prospects.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is KORU Medical Systems Inc (KRMD) stock price today?

The current price of KRMD is 5.68 USD — it has decreased -0.7 % in the last trading day.

arrow icon

What is KORU Medical Systems Inc (KRMD)'s business?

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

arrow icon

What is the price predicton of KRMD Stock?

Wall Street analysts forecast KRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is KORU Medical Systems Inc (KRMD)'s revenue for the last quarter?

KORU Medical Systems Inc revenue for the last quarter amounts to 10.40M USD, increased 27.17 % YoY.

arrow icon

What is KORU Medical Systems Inc (KRMD)'s earnings per share (EPS) for the last quarter?

KORU Medical Systems Inc. EPS for the last quarter amounts to -0.02 USD, decreased -33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for KORU Medical Systems Inc (KRMD)'s fundamentals?

The market is revising Upward the revenue expectations for KORU Medical Systems, Inc. (KRMD) for FY2025, with the revenue forecasts being adjusted by 1.69% over the past three months. During the same period, the stock price has changed by 39.90%.
arrow icon

How many employees does KORU Medical Systems Inc (KRMD). have?

KORU Medical Systems Inc (KRMD) has 80 emplpoyees as of December 05 2025.

arrow icon

What is KORU Medical Systems Inc (KRMD) market cap?

Today KRMD has the market capitalization of 263.11M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free